BEDFORD, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find ...

Lantheus Holdings, Inc. (NASDAQ:LNTH), a leading provider of diagnostic and therapeutic products with a focus on medical imaging and current market capitalization of $5.17 billion, has been ...

BEDFORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find ...

(MENAFN- GlobeNewsWire - Nasdaq) BEDFORD, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the ...

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a ...

BEDFORD, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed ...

You know it's going get to the tumor, and then if you can attach basically a warhead to it, then you know, you can deliver targeted radiation to that tumor,” Lantheus’ CEO Brian Markison says ...

Lantheus is promising up to $1.8 billion in milestone payments to POINT if the two radiotherapeutics get FDA approval and meet commercial objectives, plus royalties on net sales.